Lipella Pharmaceuticals Completes Dosing for First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus
Lipella Pharmaceuticals completes initial dosing in Phase 2a trial of LP-310 for Oral Lichen Planus, showing promising results.Quiver AI SummaryLipella Pharmaceuticals Inc. has announced the completion...
Lipella Pharmaceuticals Advances With Multiple Near-Term Catalysts and Strategic Focus on Rare Diseases
Lipella Pharmaceuticals is a clinical-stage biotechnology company that focuses on developing and commercializing treatments for serious diseases with significant unmet needs.
Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:LIPO) EQNX::TICKER_END
Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite
/PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases...